"I am delighted to join the ZyGEM team at such an exciting time in the company's development," said Dr. Ahn. "I look forward to supporting ZyGEM's efforts as it expands its enzyme-based solutions and other novel technologies into new market segments that will bring the benefits of its innovative approaches more directly to physicians and patients."
Dr. Ahn is Professor and Chair, Science & Technology Entrepreneurship with a joint appointment from the faculties of Commerce & Administration and Science at Victoria University of Wellington. Prior to joining the university, Dr. Ahn was founder, President, and Chief Executive Officer of Hana Biosciences. Prior to Hana, he served as Vice President, Hematology and corporate officer at Genentech. Previously, he held a series of positions of increasing responsibility at Amgen and Bristol-Myers Squibb. Dr. Ahn also serves on the Boards of Directors of RXi Pharmaceuticals and Access Pharmaceuticals. He received B.A. and M.B.A. degrees from Chaminade University of Honolulu and holds a Ph.D. from the University of South Australia.
ZyGEM Corporation Limited is a rapidly growing biotechnology company
with a range of innovative enzyme-based products and technologies based on
the company's exclusive collection of microorganisms from extreme
environments. ZyGEM's technology has significant competitive advantages
over existing methods and has potential applications in a number of
sizeable global markets. ZyGEM currently produces DNA extraction and
detection products, molecular biology enzymes and individual enzymes and
diagnostics, serving life sciences customers in basic research, forensics,
clinical diagnostics and agriculture. ZyGEM has facilities in New Zealand
and the U.S. For more information, visit
|SOURCE ZyGEM Corp. Ltd.|
Copyright©2008 PR Newswire.
All rights reserved